Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

The HARMONY Alliance: Novel Insights into Genomic Classification and Prognosis in Acute Myeloid Leukemia

2020 Year in Review - AML - Leukemia

Analyses of large cohorts of data are needed to understand how genetic aberrations can affect treatment outcomes in patients with hematologic malignancies (HMs). With this in mind, the HARMONY Alliance has developed a large platform for HMs called “Big Data for Better Outcome,” and aims to analyze approximately 100,000 cases of acute myeloid leukemia (AML), acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, myelodysplastic syndromes, non-Hodgkin lymphoma, and pediatric HMs. This report focused on results from the first approximately 5000 AML cases and served as proof of principle.

The Observational Medical Outcomes Partnership (OMOP) common data model was used to implement de facto anonymization and data harmonization. Thereafter, the following analyses were performed: gene–gene interaction analyses for co-occurrence and mutual exclusivity, a hierarchical Dirichlet process for class discovery, and a Bradley-Terry analysis to estimate clonal evolution. Prognostic multistage models were fitted to assess the effects of genomic and clinical data on rates of remission, relapse, and survival.

Data from 2941 patients with AML with available clinical and molecular information were analyzed. The median age was 52.4 years, and 53% of patients were male. A total of 808, 1193, and 940 patients had favorable, intermediate, and adverse cytogenetics, respectively, according to the European LeukemiaNet (ELN) 2017 risk classification. A total of 1251 patients received an allogeneic stem-cell transplantation (allo-SCT); 1690 patients received conventional consolidation.

Analysis of gene–gene interactions confirmed known patterns of co-occurrence and mutual exclusivity. Furthermore, cluster analysis enabled segmentation of “unique” ELN risk groups. Overall, these data were able to establish that epigenetic driver mutations in genes affecting DNA methylation occur very early, whereas histone-modifying enzyme mutations occur later. Finally, these data confirm that the presence of high-risk mutations differentially influences overall survival (OS) following an allo-SCT in a complex manner. Indeed, patients whose disease exhibits many high-risk genotypes, such as the TP53 mutation, seem to derive modest benefit from an allo-SCT (median OS of 54.4 weeks and 12.8 weeks with vs without allo-SCT, respectively; P <.001). However, patients whose disease exhibits other higher-risk genotypes, such as DNMT3A in combination with PTPN11, benefit more significantly from an allo-SCT (median OS of 212.7 weeks and 60.8 weeks with vs without allo-SCT, respectively; P = .027).

Results from this proof-of-principle study combining large data cohorts of clinical outcomes and disease genomic profiling from patients with AML confirm the benefit of similar approaches using the HARMONY Alliance platform, and demonstrate that analyses of OMOP-harmonized big data sets will help inform individualized therapy for optimal outcomes in other HMs.

Bullinger L, Martinez Elicegui J, Strang E, et al. Novel Insights into Genomic Classification and Prognosis in Acute Myeloid Leukemia Based on a Pan-European Public-Private Partnership, the HARMONY Alliance. Presented at: 25th European Hematology Association Congress Virtual; June 11-21, 2020. Abstract S130.

Related Items
Tibsovo Received a New Indication, in Combination with Azacitidine, for Newly Diagnosed Patients with AML and IDH1 Mutation
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Leukemia
Vidaza Received New Indication for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Leukemia, Pediatric Cancer
Arsenic Trioxide–Induced QTc Interval Prolongation and the Potential Benefit of Beta-Blockers in Patients with Acute Promyelocytic Leukemia: Case Series
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in Case Reports, Leukemia, Adverse Events
Effect of Concomitant Azole Antifungals on Duration of Myelosuppression in Newly Diagnosed Patients with AML Receiving Venetoclax in Combination with Cladribine and Low-Dose Cytarabine
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Leukemia
Dasatinib-Induced Gynecomastia in 2 Patients with Chronic Myeloid Leukemia: Case Reports and Review of the Literature
Jessie Signorelli, PharmD, BCOP, Amir T. Fathi, MD, Gabriela Hobbs, MD
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in Case Reports, Leukemia, Adverse Events
Lidocaine plus Tetracaine–Medicated Patch Used for Propofol Sedation During Lumbar Punctures in Pediatric Patients with Blood Cancer
Lisa R. Garavaglia, PharmD , Frank Casey, MD, Lesley Cottrell, PhD, Claudiu Faraon-Pogaceanu, MD, Stephan Paul, MD, Melvin Lee Wright, DO
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in Original Article, Pediatric Cancer, Leukemia, Lymphoma
Myeloablative and Reduced-Intensity Preparative Regimens for Allogeneic Transplant in the Outpatient versus Inpatient Setting in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
Gretchen Pardo, PharmD, Beth Eddy, PharmD, BCOP, Zahra Mahmoudjafari, PharmD, BCOP, Dennis Grauer, PhD, MS, Joseph McGuirk, DO
JHOP - August 2021 Vol 11, No 4 published on August 17, 2021 in Original Article, Transplant, Leukemia, Myelodysplastic Syndromes, Conditioning Regimen
Pharmacy Resident–Led Medication Reconciliation and Patient Education Service in Adults with Leukemia Receiving Anticancer Oral Agents: A Pilot Study
Lily Y. Jia, PharmD, BCOP, Jessie Signorelli, PharmD, BCOP, Samantha O. Luk, PharmD, BCOP, E. Bridget Kim, PharmD, BCPS, BCOP, Gayle C. Blouin, PharmD, BCOP
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in Original Article, Leukemia, Oncology Pharmacy Programs
Pegaspargase-Induced Diabetic Ketoacidosis in a Patient with Acute Lymphoblastic Leukemia
Ellen Madarang, PharmD, BCOP, Leslie Gallardo, PharmD, BCPS, Terrence Bradley, MD
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in Case Reports, Acute Lymphoblastic Leukemia, Leukemia, Adverse Events
Oral Azacitidine Prolongs Survival in Patients with Acute Myeloid Leukemia
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2021 Vol 11, No 2 published on April 27, 2021 in From the Literature, Leukemia
© Amplity Health. All rights reserved.